JP2015501833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501833A5 JP2015501833A5 JP2014546692A JP2014546692A JP2015501833A5 JP 2015501833 A5 JP2015501833 A5 JP 2015501833A5 JP 2014546692 A JP2014546692 A JP 2014546692A JP 2014546692 A JP2014546692 A JP 2014546692A JP 2015501833 A5 JP2015501833 A5 JP 2015501833A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- VHPXWPAGHGHDCK-UHFFFAOYSA-N 5-chloro-4-[(3,4-dichlorophenoxy)methyl]-2-fluoro-n-methylsulfonylbenzamide Chemical compound C1=C(F)C(C(=O)NS(=O)(=O)C)=CC(Cl)=C1COC1=CC=C(Cl)C(Cl)=C1 VHPXWPAGHGHDCK-UHFFFAOYSA-N 0.000 claims 3
- 229940124777 Nav1.7 inhibitor Drugs 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576005P | 2011-12-15 | 2011-12-15 | |
| US61/576,005 | 2011-12-15 | ||
| PCT/IB2012/057035 WO2013088315A1 (en) | 2011-12-15 | 2012-12-06 | Sulfonamide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501833A JP2015501833A (ja) | 2015-01-19 |
| JP2015501833A5 true JP2015501833A5 (enExample) | 2016-01-21 |
| JP6058023B2 JP6058023B2 (ja) | 2017-01-11 |
Family
ID=47557422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546692A Expired - Fee Related JP6058023B2 (ja) | 2011-12-15 | 2012-12-06 | スルホンアミド誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9085517B2 (enExample) |
| EP (1) | EP2791108B1 (enExample) |
| JP (1) | JP6058023B2 (enExample) |
| CA (1) | CA2857603C (enExample) |
| ES (1) | ES2593533T3 (enExample) |
| WO (1) | WO2013088315A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140091022A (ko) | 2011-10-31 | 2014-07-18 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| RU2014121983A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств |
| EP2800740A1 (en) * | 2012-01-04 | 2014-11-12 | Pfizer Limited | N-aminosulfonyl benzamides |
| BR112014029161A2 (pt) | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| KR101663436B1 (ko) * | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
| CA2898680A1 (en) | 2013-03-15 | 2014-09-18 | Genentech,Inc. | Substituted benzoxazoles and methods of use thereof |
| MX2016006936A (es) | 2013-11-27 | 2016-10-05 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas. |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| JP2018520107A (ja) | 2015-05-22 | 2018-07-26 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| CR20180242A (es) | 2015-09-28 | 2018-08-10 | Genentech Inc | Compuestos terapéuticos y sus métodos de uso |
| CA3003119C (en) | 2015-11-13 | 2019-10-22 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blocker |
| CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| MX388175B (es) | 2016-10-17 | 2025-03-19 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| WO2018175707A1 (en) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| CN111132961A (zh) | 2017-08-31 | 2020-05-08 | 拉夸里亚创药株式会社 | 作为ttx-s阻断剂的双芳氧基衍生物 |
| TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
| PE20251292A1 (es) | 2018-03-08 | 2025-05-14 | Incyte Corp | Compuestos diolicos de aminopirazina como inhibidores de pi3k-gamma |
| JP2021519788A (ja) | 2018-03-30 | 2021-08-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TW202038950A (zh) * | 2018-12-26 | 2020-11-01 | 日商拉夸里亞創藥股份有限公司 | 作為Nav1.7及Nav1.8阻斷劑之雜環衍生物 |
| CN114829345A (zh) * | 2019-12-27 | 2022-07-29 | 日本烟草产业株式会社 | 酰基磺酰胺化合物及其医药用途 |
| CN113200956B (zh) * | 2021-05-18 | 2022-04-22 | 潍坊医学院 | 一种磺胺苯甲酰胺类衍生物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JPH05289262A (ja) | 1992-04-10 | 1993-11-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| ES2141197T3 (es) | 1993-03-19 | 2000-03-16 | Merck & Co Inc | Derivados del acido fenoxifenilacetico. |
| JPH10503779A (ja) | 1994-08-08 | 1998-04-07 | メルク エンド カンパニー インコーポレーテッド | フェノキシフェニル酢酸誘導体 |
| WO1996009818A1 (en) | 1994-09-27 | 1996-04-04 | Merck & Co., Inc. | Endothelin receptor antagonists for the treatment of emesis |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| EP1357908A4 (en) | 2001-01-30 | 2009-07-15 | Merck & Co Inc | "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS" |
| NZ579370A (en) | 2003-08-08 | 2011-06-30 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
| RS51647B (sr) | 2006-10-18 | 2011-10-31 | Pfizer Products Inc. | Jedinjenja biaril etar uree |
| EP1995241B1 (en) * | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibitors of ion channels |
| EP2183241B1 (en) | 2007-05-03 | 2012-12-19 | Pfizer Limited | 2-pyridine carboxamide derivatives as sodium channel modulators |
| WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| GB0725214D0 (en) | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
| US8623818B2 (en) | 2008-05-16 | 2014-01-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonists, compositions, and methods for their use |
| MX2012003560A (es) * | 2009-09-25 | 2012-10-05 | Astellas Pharma Inc | Compuesto de amida sustituida. |
| JP5289262B2 (ja) | 2009-09-30 | 2013-09-11 | 京セラドキュメントソリューションズ株式会社 | シート搬送装置とこれを備えた画像読取装置及び画像形成装置 |
| WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
| US9163015B2 (en) | 2010-02-11 | 2015-10-20 | Vanderbilt University | Pyrazolopyridine, pyrarolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| KR20120120416A (ko) | 2010-02-11 | 2012-11-01 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ4 알로스테릭 강화제로서 벤즈이속사졸 및 아자벤즈이속사졸, 조성물, 및 신경 기능이상을 치료하는 방법 |
| JP2013523846A (ja) | 2010-04-16 | 2013-06-17 | メチルジーン・インコーポレイテッド | タンパク質チロシンキナーゼ活性の阻害剤および眼部の障害を治療するためのそれらの使用 |
| JP2013532185A (ja) * | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| CA2800971A1 (en) * | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| KR101663436B1 (ko) * | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
-
2012
- 2012-12-06 CA CA2857603A patent/CA2857603C/en not_active Expired - Fee Related
- 2012-12-06 WO PCT/IB2012/057035 patent/WO2013088315A1/en not_active Ceased
- 2012-12-06 ES ES12813989.6T patent/ES2593533T3/es active Active
- 2012-12-06 EP EP12813989.6A patent/EP2791108B1/en not_active Not-in-force
- 2012-12-06 US US14/358,494 patent/US9085517B2/en not_active Expired - Fee Related
- 2012-12-06 JP JP2014546692A patent/JP6058023B2/ja not_active Expired - Fee Related